Experienced in Cystectomy

Dr. Albert H. Kim

Urology
The Metrohealth System
2500 Metrohealth Dr, 
Cleveland, OH 
Accepting New Patients
Experienced in Cystectomy
The Metrohealth System
2500 Metrohealth Dr, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Albert Kim is an Urologist in Cleveland, Ohio. Dr. Kim is rated as an Experienced provider by MediFind in Cystectomy. His top areas of expertise are Cushing's disease, Muscle Invasive Bladder Cancer, Bladder Cancer, Prostate Cancer, and Cystectomy. Dr. Kim is currently accepting new patients.

His clinical research consists of co-authoring 221 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Cystectomy.

Specialties
Urology
Licenses
Urology in CA
Hospital Affiliations
Metrohealth System
Languages Spoken
English
Korean
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE METROHEALTH SYSTEM
2500 Metrohealth Dr, Cleveland, OH 44109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Biological, Device
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Device
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Device, Drug, Other
Study Phase: Phase 1
A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma
A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma
Enrollment Status: Completed
Publish Date: July 20, 2018
Intervention Type: Drug, Dietary supplement
Study Phase: Early Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: November 17, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

221 Total Publications

A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma.
A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma.
Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025
Similar Doctors
Jihad Kaouk
Elite in Cystectomy
Dr. Jihad Kaouk
Urology
Elite in Cystectomy
Dr. Jihad Kaouk
Urology

Cleveland Clinic Main Campus

2050 East 96th Street, 
Cleveland, OH 
 (5.7 miles away)
216-444-5600
Experience:
36+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jihad Kaouk is an Urologist in Cleveland, Ohio. Dr. Kaouk has been practicing medicine for over 36 years and is rated as an Elite provider by MediFind in Cystectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Horseshoe Kidney, Nephrectomy, and Prostatectomy.

Christopher Weight
Distinguished in Cystectomy
Dr. Christopher Weight
Urology
Distinguished in Cystectomy
Dr. Christopher Weight
Urology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (4.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Weight is an Urologist in Cleveland, Ohio. Dr. Weight is rated as an Elite provider by MediFind in Cystectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Nephrectomy, and Cystectomy.

Distinguished in Cystectomy
Dr. Georges-pascal Haber
Urology
Distinguished in Cystectomy
Dr. Georges-pascal Haber
Urology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (4.9 miles away)
Languages Spoken:
English
See accepted insurances

Georges-pascal Haber is an Urologist in Cleveland, Ohio. Dr. Haber is rated as an Elite provider by MediFind in Cystectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Urothelial Cancer, Nephrectomy, and Cystectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile